



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, June 28, 2019

In accordance with Article 17 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and Article 226 of the recast Spanish Securities Market Act (*Ley del Mercado de Valores*), the following **REGULATORY ANNOUNCEMENT** is hereby reported:

This announcement is further to the regulatory announcements published on 28 January 2019, 23 May 2019 and 26 June 2019, with submission receipt reference numbers 274,204, 278,505 and 279,587 respectively. Pharma Mar, S.A. (“**Pharma Mar**”) announces that it has today executed the sale and effective transfer of its subsidiary Zelnova Zeltia, S.A. (“**Zelnova**”), which includes the sale of the Italian subsidiary Copyr, S.p.A., to the companies Allentia Invest, S.L. and Safoles, S.A. (together, the “**Purchaser**”), companies directly and indirectly owned by, among others, Mr Pedro Fernández Puentes, a director of Pharma Mar, and persons connected to him, once the condition to which the completion of the transaction was subject to has been met in accordance with the purchase agreement relating to all the shares in Zelnova signed on 23 May 2019.

The Purchaser has today paid Pharma Mar the price for all the shares in Zelnova, which totals €33,417,000.

As disclosed to the market on 23 May 2019, this sale will lead to a net capital gain of approximately €28 million in Pharma Mar’s individual accounts and a loss of approximately €2.5 million in the group’s consolidated income statement.

With the completion of this sale, Zelnova and its subsidiary Copyr, S.p.A. are no longer part of the Pharma Mar Group.

The sale process was led by Alantra Corporate Finance, S.A.U., which acted as financial adviser to Pharma Mar.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com